+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Gout Therapeutic Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019-2027

  • ID: 4852086
  • Report
  • May 2019
  • Region: Global
  • 165 pages
  • Transparency Market Research
1 of 2

Global Gout Therapeutics Market: Overview

This report studies the current as well as future prospects of the global gout therapeutics market. Stakeholders of this report include companies and intermediaries engaged in the manufacture, commercialization, and provision of gout therapeutics and new players planning to enter the market.

The report comprises an elaborate executive summary, along with a market snapshot, providing overall information on various segments considered in the scope of the study. The section also provides information and data analysis of the global gout therapeutics market in terms of drug type, distribution channel, and region.

Global Gout Therapeutics Market: Key Segments

The global gout therapeutics market has been segmented based on drug type, distribution channel, and region. In terms of drug type, the global market has been classified into colchicine, antihyperuricemic agents (urate-lowering drugs), non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and biologic response modifiers (Biologics).  

Based on distribution channel, the global gout therapeutics market has been divided into hospital pharmacy, retail pharmacy, and online pharmacy. The retail pharmacy segment is expected to dominate the global gout therapeutics market during the forecast period.

Research Approach

The bottom-up approach has been employed to determine the size of the global gout therapeutics market, using various market indicators obtained from secondary sources, which included analysis of launched products and mapping of demand for gout therapeutics of top market players in specific regions.

The top-down approach has been used to derive the market size of different product segments, wherein market size of parent market was obtained through secondary sources and analyzed for sales by narrowing down to revenue percentage for product segment through extensive analysis of investor presentations, press releases, primary interviews, and others.

Data triangulation is based on both secondary research (top-down and bottom-up approaches) and primary research. Moreover, historical year-on-year growth has been taken into consideration while estimating the market size. Market value and forecast, in terms of US$ Mn, for each segment has been provided for the period from 2017 to 2027.

The report also provides compound annual growth rate (CAGR %) for each segment for the forecast period from 2019 to 2027, considering 2018 as the base year.

The overview section of the report explores market dynamics such as drivers, restraints, opportunities, and key trends that have significant impact on the global gout therapeutics market and could influence it in the near future.

Market attractiveness analysis has been provided to explain the intensity of competition in the market across regions. These analyses are likely to help market players take strategic decisions to strengthen their positions and grow their share in the global gout therapeutics market. The report also comprises pipeline analysis and epidemiological overview of gout.

Global Gout Therapeutics Market: Regional Outlook

In terms of region, the global gout therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Market size and forecast for each of these regions have been provided for the period from 2017 to 2027, along with their respective CAGRs for the forecast period from 2019 to 2027, considering 2018 as the base year.

The report also provides market size and forecast for major countries in the above mentioned regions. A detailed qualitative analysis of factors responsible for driving and restraining the market and growth opportunities has been provided in the overview section.

Companies Mentioned in the Report

Some of the major players operating in the global gout therapeutics market are

  • Takeda Pharmaceutical Company Limited
  • Teijin Pharma Limited.
    Novartis AG, Mylan N.V.
  • Horizon Pharma plc
  • Teva Pharmaceutical Industries Ltd.
  • Hikma Pharmaceuticals PLC
  • Iroko Pharmaceuticals, LLC
  • MERCK & CO., Inc.
Note: Product cover images may vary from those shown
2 of 2
1.Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Gout Therapeutics Market

4. Market Overview
4.1. Introduction
4.1.1. Component Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Gout Therapeutics Market Analysis and Forecast, 2017-2027
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Porter’s Five Force Analysis

5. Market Outlook
5.1.Epidemiological Overview of Gout Arthritis
5.2.Pipeline Analysis

6. Global Gout Therapeutics Market Analysis and Forecast, by Component
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Global Gout Therapeutics Market Value Forecast, by Drug Type, 2017-2027
6.3.1. Colchicine
6.3.2. Antihyperuricemic agents (Urate-Lowering Drugs)
6.3.3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
6.3.4. Corticosteroids
6.3.5. Biologic Response Modifiers (Biologics)
6.4. Global Gout Therapeutics Market Attractiveness, by Drug Type

7 Global Gout Therapeutics Market Analysis and Forecast, by Distribution Channel
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Global Gout Therapeutics Market Value Forecast, by Distribution Channel, 2017-2027
7.3.1. Hospital Pharmacy
7.3.2. Retail Pharmacy
7.3.3. Online Pharmacy
7.4. Global Gout Therapeutics Market Attractiveness, by Distribution Channel

8. Global Gout Therapeutics Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Global Gout Therapeutics Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Global Gout Therapeutics Market Attractiveness, by Country/Region

9. North America Gout Therapeutics Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. North America Gout Therapeutics Market Value Forecast, by Drug Type, 2017-2027
9.2.1. Colchicine
9.2.2. Antihyperuricemic agents (Urate-Lowering Drugs)
9.2.3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
9.2.4. Corticosteroids
9.2.5. Biologic Response Modifiers (Biologics)
9.3. North America Gout Therapeutics Market Value Forecast, by Distribution Channel, 2017-2027
9.3.1. Hospital Pharmacy
9.3.2. Retail Pharmacy
9.3.3. Online Pharmacy
9.4. North America Gout Therapeutics Market Value Forecast, by Country, 2017-2027
9.4.1. U.S.
9.4.2. Canada
9.5. North America Gout Therapeutics Market Attractiveness Analysis
9.5.1. By Drug Type
9.5.2. By Distribution Channel
9.5.3. By Country

10. Europe Gout Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Europe Gout Therapeutics Market Value Forecast, by Drug Type, 2017-2027
10.2.1. Colchicine
10.2.2. Antihyperuricemic agents (Urate-Lowering Drugs)
10.2.3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
10.2.4. Corticosteroids
10.2.5. Biologic Response Modifiers (Biologics)
10.3. Europe Gout Therapeutics Market Value Forecast, by Distribution Channel, 2017-2027
10.3.1. Hospital Pharmacy
10.3.2. Retail Pharmacy
10.3.3. Online Pharmacy
10.4. Europe Gout Therapeutics Market Value Forecast, by Country/Sub-region, 2017-2027
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Europe Gout Therapeutics Market Attractiveness Analysis
10.5.1. By Drug Type
10.5.2. By Distribution Channel
10.5.3. By Country/Sub-region

11. Asia Pacific Gout Therapeutics Market Analysis and Forecast
11.1.Introduction
11.1.1. Key Findings
11.2. Asia Pacific Gout Therapeutics Market Value Forecast, by Drug Type, 2017-2027
11.2.1. Colchicine
11.2.2. Antihyperuricemic agents (Urate-Lowering Drugs)
11.2.3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
11.2.4. Corticosteroids
11.2.5. Biologic Response Modifiers (Biologics)
11.3. Asia Pacific Gout Therapeutics Market Value Forecast, by Distribution Channel, 2017-2027
11.3.1. Hospital Pharmacy
11.3.2. Retail Pharmacy
11.3.3. Online Pharmacy
11.4. Asia Pacific Gout Therapeutics Market Value Forecast, by Country/Sub-region, 2017-2027
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Asia Pacific Gout Therapeutics Market Attractiveness Analysis
11.5.1. By Drug Type
11.5.2. By Distribution Channel
11.5.3. By Country/Sub-region

12. Latin America Gout Therapeutics Market Analysis and Forecast
12.1.Introduction
12.1.1. Key Findings
12.2. Latin America Gout Therapeutics Market Value Forecast, by Drug Type, 2017-2027
12.2.1. Colchicine
12.2.2. Antihyperuricemic agents (Urate-Lowering Drugs)
12.2.3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
12.2.4. Corticosteroids
12.2.5. Biologic Response Modifiers (Biologics)
12.3. Latin America Gout Therapeutics Market Value Forecast, by Distribution Channel, 2017-2027
12.3.1. Hospital Pharmacy
12.3.2. Retail Pharmacy
12.3.3. Online Pharmacy
12.4. Latin America Gout Therapeutics Market Value Forecast, by Country/Sub-region, 2017-2027
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Latin America Gout Therapeutics Market Attractiveness Analysis
12.5.1. By Drug Type
12.5.2. By Distribution Channel
12.5.3. By Country/Sub-region

13. Middle East & Africa Gout Therapeutics Market Analysis and Forecast
13.1.Introduction
13.1.1. Key Findings
13.2. Middle East & Africa Gout Therapeutics Market Value Forecast, by Drug Type, 2017-2027
13.2.1. Colchicine
13.2.2. Antihyperuricemic agents (Urate-Lowering Drugs)
13.2.3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
13.2.4. Corticosteroids
13.2.5. Biologic Response Modifiers (Biologics)
13.3. Middle East & Africa Gout Therapeutics Market Value Forecast, by Distribution Channel, 2017-2027
13.3.1. Hospital Pharmacy
13.3.2. Retail Pharmacy
13.3.3. Online Pharmacy
13.4. Middle East & Africa Gout Therapeutics Market Value Forecast, by Country/Sub-region, 2017-2027
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5.Market Attractiveness Analysis
13.5.1. By Drug Type
13.5.2. By Distribution Channel
13.5.3. By Country/Sub-region

14. Competition Landscape
14.1. Company Profiles
14.1.1. Takeda Pharmaceutical Company Limited
14.1.1.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.1.1.2 Product Portfolio
14.1.1.3. SWOT Analysis
14.1.1.4. Strategic Overview
14.1.1.5. Financial Overview
14.1.2. Teijin Pharma Limited
14.1.2.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.1.2.2 Product Portfolio
14.1.2.3. SWOT Analysis
14.1.2.4. Strategic Overview
14.1.3. Novartis AG
14.1.3.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.1.3.2 Product Portfolio
14.1.3.3. SWOT Analysis
14.1.3.4. Strategic Overview
14.1.3.5. Financial Overview
14.1.4. Mylan N.V.
14.1.4.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.1.4.2 Product Portfolio
14.1.4.3. SWOT Analysis
14.1.4.4. Strategic Overview
14.1.4.5. Financial Overview
14.1.5. Horizon Pharma plc.
14.1.5.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.1.5.2 Product Portfolio
14.1.5.3. SWOT Analysis
14.1.5.4. Strategic Overview
14.1.5.5. Financial Overview
14.1.6. Teva Pharmaceutical Industries Ltd.
14.1.6.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.1.6.2 Product Portfolio
14.1.6.3. SWOT Analysis
14.1.6.4. Strategic Overview
14.1.6.5. Financial Overview
14.1.7 Hikma Pharmaceuticals PLC
14.1.7.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.1.7.2 Product Portfolio
14.1.7.3. SWOT Analysis
14.1.7.4. Strategic Overview
14.1.7.5. Financial Overview
14.1.8. Iroko Pharmaceuticals, LLC
14.1.7.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.1.7.2 Product Portfolio
14.1.7.3. SWOT Analysis
14.1.7.4. Strategic Overview
14.1.9. MERCK & CO., Inc.
14.1.9.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.1.9.2 Product Portfolio
14.1.9.3. SWOT Analysis
14.1.9.4. Strategic Overview
14.1.9.5. Financial Overview
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll